Author/Authors :
Gong, Su-Gang Department of Cardio-Pulmonary Circulation - The Third Affiliated Hospital of Soochow University - Shanghai Pulmonary Hospital, Suzhou, Jiangsu, China , Wang, Lan Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Pudasaini, Bigyan Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Yuan, Ping Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Jiang, Rong Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Zhao, Qin-Hua Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , He, Jing Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Zhang, Rui Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Wu, Wen-hui Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Liu, Jin-Ming Department of Cardio-Pulmonary Circulation - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China , Zhou, Cai-cun Department of Oncology - Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China
Abstract :
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients
with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two
ETRAs. We aimed to evaluate the safety and efficacy from ambrisentan to bosentan. Methods: Twenty PAH patients were enrolled
into the single-center, open-labelled prospective study. Echocardiogram, WHO functional class (WHO-FC), 6-minute walking
distance (6MWD), right heart catheterization, and hemotology were collected. After receiving oral 5 mg ambrisentan daily
initially for one year, the patients were divided into two arms: eight patients switched to bosentan, while the remaining 12 patients
continued ambrisentan. Characteristics at baseline, 1-and 2-year follow-up points were compared. Results: .ere were no
significant differences in echocardiogram, WHO-FC, hemodynamics, demographics and liver function at baseline, 1-and 2-year
points in both arms. 6MWD in bosentan group was significantly shorter at baseline. But there were no significant differences of
6MWD at 1- and 2-year points. Conclusions: It is safe for stable PAH patients to transition from ambrisentan to bosentan without
hemodynamic or hematologic deterioration.
